KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Purchases 43,707 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALVGet Free Report) major shareholder Venrock Healthcare Capital Par acquired 43,707 shares of the stock in a transaction dated Thursday, January 30th. The stock was acquired at an average price of $8.76 per share, with a total value of $382,873.32. Following the completion of the acquisition, the insider now owns 4,986,480 shares in the company, valued at approximately $43,681,564.80. The trade was a 0.88 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

  • On Monday, February 3rd, Venrock Healthcare Capital Par acquired 14,562 shares of KalVista Pharmaceuticals stock. The stock was acquired at an average price of $9.22 per share, with a total value of $134,261.64.

KalVista Pharmaceuticals Trading Up 3.5 %

Shares of KalVista Pharmaceuticals stock opened at $9.22 on Tuesday. The company’s fifty day simple moving average is $8.81 and its two-hundred day simple moving average is $10.81. The company has a market cap of $455.65 million, a P/E ratio of -2.53 and a beta of 0.85. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALVGet Free Report) last released its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.01. Analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on KALV shares. JMP Securities started coverage on shares of KalVista Pharmaceuticals in a report on Friday. They set an “outperform” rating and a $19.00 price target for the company. Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a “strong-buy” rating in a report on Friday. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Bank of America started coverage on shares of KalVista Pharmaceuticals in a report on Wednesday, December 18th. They set a “buy” rating and a $22.00 price target for the company. Finally, Needham & Company LLC reiterated a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, KalVista Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $23.80.

Get Our Latest Stock Analysis on KalVista Pharmaceuticals

Institutional Trading of KalVista Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. grew its position in shares of KalVista Pharmaceuticals by 24.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock worth $87,000 after buying an additional 2,043 shares during the period. SG Americas Securities LLC boosted its stake in KalVista Pharmaceuticals by 10.0% in the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after purchasing an additional 1,319 shares in the last quarter. Intech Investment Management LLC bought a new position in KalVista Pharmaceuticals in the 3rd quarter worth about $126,000. Quest Partners LLC bought a new position in KalVista Pharmaceuticals in the 3rd quarter worth about $175,000. Finally, The Manufacturers Life Insurance Company boosted its stake in KalVista Pharmaceuticals by 27.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock worth $182,000 after purchasing an additional 3,314 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

(Get Free Report)

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

Recommended Stories

Insider Buying and Selling by Quarter for KalVista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.